Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai Corporation of North America, and Pivotal BioSciences, a biotechnology company developing oncology products, have signed an agreement in which Morphotek will access Pivotal BioSciences's LEC platform technology for the development of therapeutic monoclonal antibodies.
Subscribe to our email newsletter
Pursuant to the terms of the agreement, Morphotek will evaluate the liver-expression chemokine (LEC) technology in-house and have the right to exercise an option for a license.
Should Morphotek choose to exercise its option, Morphotek would obtain a worldwide license under Pivotal’s LEC technology to develop new therapeutic products, and would retain the responsibility for the commercialization of such products derived using the technology.
Nicholas Nicolaides, president and CEO of Morphotek, said: “This collaboration further illustrates our commitment to discover, develop and commercialize efficacious monoclonal antibodies to address unmet diseases. We are extremely honored to be Pivotal BioSciences’s first partner for the R&D of therapeutic antibodies.”